Loading
A phase 3 trial of Duvelisib, Gemcitabine and Bendamustine in non-Hodgkin lymphoma, run by SecuraBio, now recruiting.
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype is a phase 3 interventional study registered as NCT06522737 by SecuraBio, with 124 participants planned, started 2025-05-19 and due to reach its primary completion in 2028-02. Interventions recorded: Duvelisib, Gemcitabine and Bendamustine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bendamustine, Small-molecule kinase inhibitors, Cytotoxic chemotherapy and the tag pipeline.
Shares Bendamustine, Small-molecule kinase inhibitors, Cytotoxic chemotherapy and the tag pipeline.
Shares Bendamustine, Small-molecule kinase inhibitors, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/